Mohammed A. El-Sawy
Al Mansurah, 12345, Egypt
NCT Number: NCT06515743
During the COVID-19 pandemic, there was a lot of reporting of COVID-19-associated mucormycosis cases. Managing this condition posed a new challenge to clinicians. Management includes therapeutic drugs and aggressive surgical debridement. Due to the unpredictability of disease prognosis and the possible recurrence of the disease, rehabilitation with delayed surgical obturators is beneficial for patients. Hence, the current study aimed to evaluate the impact of delayed surgical obturators on quality of life of COVID-19-associated mucormycosis patients post-maxillectomies
Looking for future studies?
Notify Me25 year–70 year
All sexes
Observational
Al Mansurah, 12345, Egypt
Globally, the prevalence of mucormycosis varied from 0.005 to 1.7 per million population, while its prevalence is nearly 80 times higher (0.14 per 1000) in India compared to developed countries, in a recent estimate of year 2019-2020.
Among the medical professionals involved in managing patients with mucormycosis, maxillofacial prosthodontists are responsible for prosthetic restoration of lost oral and maxillofacial structures, helping patients to socialize and have an acceptable quality of life after surgical treatment
Only the study team can determine whether someone qualifies for participation.
Obturator prosthetic rehabilitation provided as part of routine clinical care following maxillectomy. Rehabilitation progressed through delayed surgical, transitional, and definitive obturator stages according to clinical healing and tissue stabilization. No intervention was assigned or modified for the purposes of this retrospective study.
Time frame: From after maxillectomy and before obturator rehabilitation through 1 week after insertion of the definitive obturator; assessments were performed at T1 (before obturator rehabilitation), T2 (1 week after delayed surgical obturator insertion), T3 (1 week
Oral health-related quality of life was assessed using the validated Arabic version of the Oral Health Impact Profile-14 (OHIP-14). The total OHIP-14 score ranges from 0 to 56, with higher scores indicating poorer quality of life. Scores were retrospectively recorded at four assessment time points: after maxillectomy and before obturator rehabilitation, after insertion of the delayed surgical obturator, after insertion of the transitional obturator, and after insertion of the definitive obturator. Changes in OHIP-14 scores across rehabilitation stages were compared within and between the oral neoplasm and COVID-19-associated mucormycosis cohorts.
Time frame: From 1 week after insertion of the delayed surgical obturator through 1 week after insertion of the definitive obturator, with assessments at 1 week after insertion of the delayed surgical, transitional, and definitive obturators.
Obturator-related functional performance was assessed using the 15-item Obturator Functioning Scale (OFS), evaluating patient-reported difficulties related to speech, eating, and prosthesis appearance. The OFS was retrospectively recorded after insertion of the delayed surgical obturator, transitional obturator, and definitive obturator. Changes in OFS scores across these rehabilitation stages were compared within and between the oral neoplasm and COVID-19-associated mucormycosis cohorts.
Menoufia University
Other
Comparison of Quality of Life After Rehabilitation With an Obturator in Maxillary Defects Due to COVID-19 Associated Mucormycosis and Oral Cancer.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04744454
Aspergillosis, Bacterial Infections and Mycoses
Seoul, South Korea
View Trial DetailsNCT06900114
Bacterial Infections and Mycoses, COVID-19
Tianjin, China
View Trial DetailsNCT04550936
Bacterial Infections and Mycoses, Infections
Limoges, France
View Trial DetailsNCT05212961
Bacterial Infections and Mycoses, Infections
Minya, Egypt
View Trial Details